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Abstract
Background: Physicians may be unaware of the severity and extent of gastroesophageal reflux disease (GERD) in
their patients. The aim of this study was to evaluate patient-physician agreement concerning proton pump
inhibitor (PPI) treatment.
Methods: 1818 French primary-care physicians and 5174 adult patients with GERD who were taking PPIs answered
questions regarding symptoms and treatment satisfaction. Patient-physician agreement was scored using the
Kappa () method.
Results: There was moderate patient-physician agreement for PPI treatment satisfaction ( = 0.60), PPI prescription
adherence ( = 0.57) and use of over-the-counter gastrointestinal medications ( = 0.44-0.51). Patient satisfaction
with PPI therapy and PPI treatment adherence rates were both ~90%. There was poor patient-physician agreement
concerning PPI therapy expectations ( = 0.22-0.33). Residual reflux symptoms occurred in 61% of patients.
Physicians underestimated residual symptom severity compared with their patients ( = 0.43-0.47), though there
was good agreement regarding the presence ( = 0.62-0.78) and frequency ( = 0.61-0.66) of these symptoms and
their effect on patients’ daily life ( = 0.64).
Conclusions: Patient-physician agreement regarding PPI therapy for GERD was moderate or good for the presence
of residual symptoms and moderate for treatment satisfaction, but poor for treatment expectations. PPI treatment
resulted in high satisfaction rates, but residual symptoms were fairly common and their severity was
underestimated by physicians.
Background
Gastroesophageal reflux disease (GERD) develops when
reflux of the stomach contents into the esophagus
causes troublesome symptoms such as heartburn or acid
regurgitation, and/or complications such as esophagitis
[1]. The prevalence of GERD is thought to be 10-20% in
Western countries based on the presence of heartburn
and/or regurgitation at least once per week in general
population surveys [2]. In France, 8% of the population
experience typical symptoms of GERD at least once per
week [3].
GERD is a chronic disease and disrupts many aspects
of patients’ everyday lives. At least two-thirds of patients
still have GERD 10 years after their initial diagnosis, and
almost half of adults with GERD have had their symp-
toms for 10 years or more [2,4]. Surveys of patients and
the general population using validated generic health
questionnaires show that GERD disrupts patients’ lives
in many ways, primarily by causing pain [5,6], but also
through interference with normal activities such as eat-
ing and drinking, work, sleep and enjoyment of social
occasions [7].
Consultation rates for GERD are low: only 5-30% of
individuals with gastroesophageal reflux consult a physi-
cian about their symptoms each year [8-10]. Symptom
burden and anxiety about serious underlying disease are
the major reasons for consultation [3,11,12]. Only 1.7%
of primary-care consultations are the result of GERD
[13], but consultation rates are increasing, probably * Correspondence: dorval@med.univ-tours.fr
1Gastroenterology, Trousseau Hospital, Tours, France
Full list of author information is available at the end of the article
Dorval et al. BMC Gastroenterology 2011, 11:25
http://www.biomedcentral.com/1471-230X/11/25
© 2011 Dorval et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.because of an apparently increasing prevalence of GERD
in the community [13,14].
Physicians are not always aware of the full burden of
illness of patients who consult them with reflux symp-
toms. A study of patient and physician ratings of reflux
symptoms in clinical trials showed that physicians tend
to underestimate the prevalence and severity of such
symptoms [15]. Agreement between patients and physi-
cians was better after treatment than before, possibly
because physicians’ r a t i n g sw e r em o r el i k e l yt oa g r e e
with those of patients when symptoms were absent [15].
A study in primary care has shown that patients do not
provide their physicians with full information on their
reflux symptoms unless they have the aid of a question-
naire [16], and that physicians find such information
very useful [17].
Recent surveys in primary care indicate that approxi-
mately a quarter of patients are not satisfied with their
prescription treatment for GERD [18,19]. Patients with
GERD continue to experience residual reflux symptoms
despite acid-suppressive therapy, and these symptoms
can substantially reduce patients’ quality of life [11].
This leads to use of over-the-counter (OTC) medica-
tions such as antacids, alginates and histamine (H2)-
receptor antagonists, repeated physician consultation
and treatment dissatisfaction [3,11,20,21]. Unsurpris-
ingly, patients with the greatest burden of illness during
treatment are least likely to be satisfied with their treat-
ment [22].
The aim of the present study was to evaluate patient-
physician agreement concerning treatment satisfaction
in a large population of adult patients with GERD trea-
ted with proton pump inhibitors (PPIs) in primary care.
This study also assessed the presence, frequency and
severity of reflux symptoms, as well as their effect on
patients’ daily life and the need for self-medication with
OTC gastrointestinal drugs.
Methods
The study was conducted from 1 September 2003 to 22
June 2004. A representative sample of 2500 primary-
care physicians working in metropolitan France was
selected by drawing lots from an independent database
with regional stratification. The following information
was collected about the physicians: sex, age, average
number of adult GERD patients, number of patients
seen each week and GERD treatment patterns. The
patients who were asked to participate were the first
adult patients coming to consult their physician (for any
reason) after enrolment of the centre in the study, who
had reflux symptoms, a PPI prescription covering the
previous month and who had taken their PPI on at least
14 days of that month.
Patients were excluded from the study if they were
under 18 years old, were unable to fill in the question-
naire, did not have reflux symptoms or esophagitis, were
not treated in the last month with a PPI prescribed in a
continuous way (or had not taken a PPI for at least 14
days in the preceding month), or were enrolled before
the designated inclusion period.
The patient questionnaire collected information
including demographic data (age, sex, weight, height,
and alcohol and tobacco consumption); recent and cur-
rent PPI treatment (agent, dosage, start date and mode
[continuous, intermittent or on-demand]); upper gastro-
intestinal endoscopy in the previous 3 years (presence
or absence of esophagitis); specialist consultations about
GERD in the previous 3 years; concurrent treatment
with non-steroidal anti-inflammatory drugs (NSAIDs),
aspirin, anticoagulants and corticosteroids.
Assessment of symptoms and satisfaction
The patient and the physician each answered questions
about the symptoms and treatment satisfaction. In the
case of the patient questionnaire, questions were asked
regarding patients’ own experiences and satisfaction.
With regard to the physician questionnaire, doctors
were asked about their degree of satisfaction with the
PPI treatment of their patient, and their own knowledge
of their patients’ quality of life and residual symptoms.
The patient and physician questionnaires both asked for
details on the following items (with the symptom
descriptors used in the patient questionnaire given in
brackets):
￿ the presence/absence (at any time), frequency (num-
ber of days per week the symptoms were experienced)
and severity (mild, moderate or severe) of daytime
heartburn (a burning feeling rising from the stomach or
lower chest up towards the neck), night-time heartburn
and acid regurgitation (a sour or bitter liquid in the
mouth) during treatment with PPIs
￿ the presence/absence of other gastrointestinal symp-
toms (at any time), including dysphagia (difficulty swal-
lowing), epigastric burning( b u r n i n gi nt h es t o m a c h ) ,
abdominal pain (pain in the stomach), nausea (desire to
vomit), vomiting, eructation (belching) and bloating (dis-
tension) during treatment with PPIs
￿ current expectations with respect to treatment, the
current impact of reflux symptoms on everyday life and
current overall patient satisfaction
￿ adherence to PPI therapy (yes/no)
￿ self-medication for reflux symptoms during treat-
ment with PPIs (agents and frequency).
Patients received an information form concerning the
study and were free to choose not to participate. Formal
written informed consent was not required because the
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ify the doctor-patient relationship. Each doctor saw their
patients within the usual framework of consultations,
which were not convened specifically for the purposes
of the investigation. Each patient completed his or her
questionnaire anonymously and sealed it in an envelope,
which along with the physician-completed questionnaire,
was sent for analysis to Axonal S.A. (Nanterre, France),
a contract research organization responsible for the
study logistics. Additional assessment and explorations
were not required by this protocol. The investigation
was the subject of a declaration specific to the Advisory
Committee for Data Processing in Health Research
(Comité consultatif sur le traitement de l’information en
matière de recherche dans le domaine de la santé) and
the approval of the National Commission of Data Pro-
cessing and Freedoms (Commission Nationale de l’Infor-
matique et des Libertés). The study also complied with
epidemiological good practice according to the recom-
mendations of the Association of French-Speaking
Epidemiologists (ADELF). The study was approved by
the National Physician Council in July 2003. Ethical
approval was not required.
Statistics
The presence, frequency and severity of reflux symp-
toms were defined on the basis of patient rather than
physician reports [23]. The effect of GERD on everyday
life, overall satisfaction and expectations with respect to
treatment (symptoms, quality of life and self-medication)
was assessed through a five-grade Likert scale. Physi-
cian-patient answers were analysed by the Kappa ()
method [24], using the following grades: very poor
(0.00-0.20), poor (0.21-0.40), moderate (0.41-0.60), good
(0.61-0.80) and excellent (0.81-1.00).
Results
Study population
In total, 1818 primary-care physicians participated in the
s t u d y ,g i v i n gar e s p o n s er a t eo f7 2 . 7 % .T h ep h y s i c i a n s
were predominantly male (86.2%), and their mean age
(± SD) was 47.0 ± 7.1 years. They saw 122.1 ± 50.4
adult patients each week, of whom 13.1 ± 9.4 were con-
sulting them about gastroesophageal reflux symptoms.
With respect to prescribing practice, most physicians
prescribed PPIs often (68.5%) or always (29.1%) for
adult patients with GERD, whereas H2-receptor antago-
nists were prescribed rarely (46.8%) or never (17.2%).
Overall, 1818 physicians recruited 5326 patients to the
study. The demographic and clinical characteristics of
the patients recruited to the study are summarized in
Table 1. Paired patient-physician data were evaluable in
5174 cases and were included in the study analyses.
Patient expectation, adherence and satisfaction
Most patients (72.0%) rated their satisfaction with their
PPI treatment for GERD to be excellent (28.1%) or good
(43.9%). A further 19.5% reported moderate satisfaction,
7.2% minimal satisfaction and 1.4% no satisfaction
(Figure 1). Similarly, physicians rated patient satisfaction
with PPI treatment as excellent for 27.3% of their
patients and good for 44.7%. This translated into moder-
ate agreement between patients and physicians with
respect to overall treatment satisfaction. In subgroup
analyses, this agreement was not influenced by the age
of the patient or the duration of PPI therapy.
Overall, 92.2% of patients reported taking their PPI
medication as prescribed, compared with a physician rat-
ing of adherence of 89.3%. This corresponded to moder-
ate agreement between patients and physicians ( =
0.57). There was widespread use of OTC medications for
GERD. According to the physicians, 51.4% of patients
with a PPI prescription also used an OTC medication for
their gastrointestinal symptoms. The physicians reported
that, of the 5326 patients who were recruited, 44.6% of
GERD patients with a PPI prescription used antacids/
Table 1 Patient sociodemographic and clinical
characteristics (N = 5326)
Characteristic Mean ± SD
or %
Age (years, mean ± SD) 53.0 ± 14.6
Sex (% male) 57.4
Weight (kg, mean ± SD) 74.8 ± 13.6
Height (cm, mean ± SD) 169.4 ± 8.4
BMI (kg/m
2, mean ± SD) 26.0 ± 4.07
Smokers* (%) 37.0
Alcohol consumers* (%) 52.2
PPI use
Continuous (%) 68.8
Intermittent (%) 20.1
On-demand (%) 11.0
Use (often or always) of OTC medication according to
the physician
Antacids and alginates (%) 8.2
Prokinetics (%) 3.4
H2-receptor antagonists (%) 0.8
Upper GI endoscopy in previous 3 years (%) 44.9
Esophagitis detected on endoscopy (%) 77.3
Concurrent medication
NSAIDs (%) 13.1
Aspirin (%) 7.7
Anticoagulants (%) 6.8
Corticosteroids (%) 1.6
*Includes occasional and regular use.
BMI, body mass index; GI, gastrointestinal; H2, histamine; NSAID, non-steroidal
anti-inflammatory drug; OTC, over-the-counter; PPI, proton pump inhibitor; SD,
standard deviation.
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Page 3 of 8alginates (8.2% often or always), 21.0% used prokinetics
(3.4% often or always) and 7.1% used H2-receptor antago-
nists (0.8% often or always). There was moderate agree-
ment between patients and physicians with respect to use
of antacids or local alginates ( =0 . 4 4 )a n dp r o k i n e t i c
agents ( = 0.51).
The majority (77.2%) of patients expected their symp-
toms to disappear during treatment (Figure 2), with
many patients also anticipating rapid symptom relief
(48.1%), improvement in daily life (34.5%) and dimin-
ished use of OTC medication (11.6%). However, there
was poor agreement between patients and physicians
with respect to expectations of a decreased impact on
daily life, symptom disappearance, speed of symptom
relief and decrease in OTC medication use during treat-
ment, with patients tending to have lower expectations
than their physicians (Figure 2).
Residual symptoms and impact
Overall, 60.7% of patients reported at least one residual
symptom: 41.6% reported daytime heartburn, 39.3%
reported nocturnal heartburn and 36.5% reported acid
regurgitation (Table 2). Physicians slightly underesti-
mated the presence of daytime (35.8%) and nocturnal
heartburn (38.8%) in patients taking PPIs, and overesti-
mated the prevalence of regurgitation (41.3%). There
was, nevertheless, good agreement between patients and
physicians for both the presence of daytime heartburn,
nocturnal heartburn and acid regurgitation during the
reporting period (Table 2), and the frequency of daytime
heartburn, nocturnal heartburn and acid regurgitation
(Figure 3). It is also interesting to note the frequency of
these symptoms (days per week these symptoms were
experienced), as reported by patients taking PPIs.
Patient-reported daytime heartburn, nocturnal heartburn
and acid regurgitation occurred on five or more days
per week in 26-35% of cases among those expressing
these residual symptoms (Figure 3).
There was only moderate agreement between patients
and physicians with respect to the severity of residual
reflux symptoms: daytime heartburn, nocturnal heart-
burn and acid regurgitation (Figure 4). There was good
agreement between patients and physicians with respect
to the effect of residual reflux symptoms on daily life
(Figure 5). Residual symptoms affected the everyday
lives of 60.0% of GERD patients treated with PPIs, and
were rated as having a high or very high impact by 8.4%
of patients (Figure 5).
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Figure 1 Patient and physician ratings of patient satisfaction
with treatment.
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Figure 2 Patient and physician ratings of patient expectations of treatment. OTC, over-the-counter.
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Page 4 of 8Discussion
This study shows that there is a high level of satisfaction
associated with the treatment of GERD with PPIs.
Patients and their physicians rated their treatment satis-
faction levels as excellent or good in more than 70% of
cases, and excellent, good or moderate in over 90% of
cases. This compares well with previously published
treatment satisfaction rates of 70-94% for GERD medical
therapies [25]. Adherence to PPI prescription, as
assessed by physicians and patients, was also very high
at approximately 90%, although this was a simple
response to a question that asked if the prescription had
been followed.
Despite high satisfaction and compliance rates, just
over half of all patients with GERD in the present study
experienced at least one residual gastrointestinal symp-
tom. This is consistent with previously published survey
data in which 46% of daily PPI users experienced break-
through symptoms, which occurred on 28% of treatment
days [21]. Although it is difficult to determine how
many patients were responders to PPI therapy in the
present study it is interesting to note that many patients
experiencing residual heartburn and acid regurgitation
had these symptoms frequently (five or more days per
week in 26-35% of cases). Furthermore, residual reflux
symptoms were moderate or severe in 48-63% of cases.
There is a moderate or good degree of agreement
between patients and physicians for most parameters
examined in the present study. Physicians had a moder-
ate-to-good understanding of their patients’ symptom
burden and satisfaction with treatment. Physicians
tended to underestimate the severity of reflux symptoms
by underestimating the prevalence of moderate and
severe symptoms and overestimating the prevalence of
mild symptoms (Figure 4). There was a poor level of
agreement between patients and physicians concerning
expectations of PPI treatment. In general, physicians
had greater expectations than patients concerning the
benefits of PPI therapy.
There are several clinical implications arising from
physicians’ underestimation of the severity of GERD,
Table 2 Prevalence of gastrointestinal symptoms and
patient-physician agreement
Symptom Presence  (95% CI)
Patient Physician
Daytime heartburn 41.6% 35.8% 0.62 (0.59-0.64)*
Night-time heartburn 39.3% 38.8% 0.78 (0.73-0.76)†
Acid regurgitation 36.5% 41.3% 0.63 (0.61-0.65)*
Dysphagia 3.4% 4.6% 0.51 (0.45-0.567)*
Epigastric burning 15.7% 17.7% 0.65 (0.63-0.68)*
Abdominal pain 14.2% 10.6% 0.52 (0.48-0.56)*
Nausea 9.0% 7.0% 0.57 (0.53-0.61)*
Vomiting 1.4% 1.2% 0.60 (0.50-0.70)†
Bloating 26.7% 23.1% 0.67 (0.65-0.69)*
Eructation 21.7% 18.0% 0.59 (0.56-0.62)*
*P < 0.0001, McNemar’s test.
†Not significant.
CI, confidence interval.
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Figure 3 Patient and physician ratings of the frequency of daytime heartburn, night-time heartburn and acid regurgitation in patients
with each symptom. Number of patients = 1314 for daytime heartburn, 1519 for night-time heartburn and 1302 for acid regurgitation.
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Page 5 of 8their high expectations of PPI therapy and the level of
residual gastrointestinal symptoms observed in PPI-trea-
ted patients in this study. It may be beneficial to use
patient-completed questionnaires to help improve the
management of newly diagnosed and existing GERD
patients in primary care [16]. Several studies show that
satisfaction with treatment is associated with meeting
patient expectations and good patient-physician commu-
nication [26-28]. Although satisfaction rates were high
in the present study, satisfaction may be improved if
physicians are able to manage patients’ expectations
through more effective communication. Response to
therapy may be increased by educating patients about
the correct way in which to take their medication to
improve patient adherence [29]. A proportion of
patients with GERD receiving prescription PPIs also
need to move to a more effective therapy to prevent
residual gastrointestinal symptoms. Additional self-medi-
cation or switching to another PPI may be helpful [30].
In addition, a therapeutic option other than acid-
suppressive drugs (including surgical treatment) may
prove useful, particularly in severe cases.
The data collected in the present study for treatment
expectations, residual symptoms and satisfaction are
similar to those of the US PUNS Study [20], the interna-
tional Burning Questions survey [11] and two French
treatment-satisfaction surveys conducted in primary and
secondary care [18,19]. However, very few other studies
have paired answers from physicians and patients within
the same study. McColl and colleagues showed that
before treatment, physicians tended to underestimate
the severity of their patients’ reflux symptoms [15].
However, after treatment, agreement between physicians
and patients improved to reach a moderate to substan-
tial level. This is similar to the findings of the present
study in which all patients were receiving treatment
with PPIs before the start of the study and agreement
between patients and physicians was moderate. Simi-
larly, correlations between physician and patient assess-
ments of the severity of reflux symptoms in another
study were low at baseline and stronger when assessed
after treatment had begun [31].
A l t h o u g ht h ep r e s e n ts t u d yw a sal a r g es u r v e yo f
paired responses in primary care with an excellent
response rate, it suffers from several disadvantages and
limitations. While patients were neither specially
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Figure 4 Patient and physician ratings of the severity of daytime heartburn, night-time heartburn and acid regurgitation in patients
with each symptom. Number of patients = 1467 for daytime heartburn, 1628 for night-time heartburn and 1478 for acid regurgitation.
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Figure 5 Patient and physician ratings of the impact of reflux
symptoms on daily life.
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Page 6 of 8selected nor specially invited for the purpose of this
s t u d y ,t h e ym a yh a v eb e e nm o r el i k e l yt oc o n s u l tt h e i r
physician if they had more severe reflux symptoms.
Thus, this study may have a selection bias towards
individuals with more severe symptoms. Furthermore,
the high prevalence of esophagitis among patients who
underwent an endoscopy in the current study could
reflect a referral bias. Adherence was self-reported and
so may be underestimated (particularly unintentional
non-adherence such as taking the medication at the
wrong time of day). Information on treatment expecta-
tions was based on patients recalling how they felt
before the start of treatment. No information was avail-
able concerning patients’ pre-treatment symptom bur-
den or consultations, which may have influenced
patients’ satisfaction. A further possible limitation is
that the study did not use a validated questionnaire,
since the most appropriate tools (e.g. the Treatment
Satisfaction Questionnaire [TSQ] in GERD) were not
available in French. The Overall Treatment Effect
(OTE) questionnaire (adapted from the Global Ratings
of Change Questionnaire [GRCQ]) is validated in
French, but does not capture the dimension of satisfac-
tion [32,33].
Conclusions
In conclusion, this study shows there were very high rates
of patient-physician satisfaction and treatment adherence
among GERD patients taking a PPI (all ~90%), and that
there was moderate patient-physician agreement for
these parameters. However, agreement levels were lower
concerning therapeutic expectations, with physicians
having greater expectations of PPI therapy than their
patients. Residual gastrointestinal symptoms were fairly
common and physicians underestimated residual symp-
tom severity compared with their patients, though there
was good agreement regarding the presence and fre-
quency of these symptoms and their effect on patients’
daily life. These results suggest the potential for better
communication between physicians and their patients
with GERD, possibly through structured symptom ques-
tionnaires, and a need for physicians to be open to the
option of switching PPI, or choosing an alternative or
additional GERD medication in selected patients with
difficult-to-treat GERD.
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